ClinicalTrials.gg
RecruitingNCT07437755PROTECT-CIRRUpdated Feb 27, 2026

Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures

An interventional study of Blood Products transfusion in Liver Cirrhosis With Acute Decompensation, sponsored by Grigore T. Popa University of Medicine and Pharmacy. Recruiting at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Grigore T. Popa University of Medicine and Pharmacy · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jun 2025, registered Feb 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Liver Cirrhosis with a site in Romania — 6 open to participants now, 6 under way, 1 of them phase 3. Liver Cirrhosis · Romania.

Planned enrollment
11th of 16
116 · median 223
Started
2025
the only one that year
No phase
2 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Grigore T. Popa University of Medicine and Pharmacy

Among the 22 studies in Liver Cirrhosis with a site in Romania, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 21st registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

6 of the 22 studies in Liver Cirrhosis with a site in Romania are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Liver Cirrhosis with a site in Romania, or all of them as a file.
02

Study summary

Patients with liver cirrhosis have historically received prophylactic transfusions before invasive procedures with high risk of bleeding. The optimal method for establishing the need of blood transfusion before invasive procedures in cirrhotic patients has not been determined yet, and there are not enough scientific data to warrant empirical transfusion. In many surgical and trauma-related contexts, viscoelastic tests, like Rotational Thromboelastometry (ROTEM), offer a comprehensive assessment of hemostasis, and it has been demonstrated to predict bleeding risk more accurately than traditional coagulation tests. The aim of this project is to evaluate the efficacy of a ROTEM-based algorithm in managing the administration of prophylactic blood components to patients diagnosed with decompensated liver cirrhosis undergoing invasive high risk of bleeding procedures. The investigators hypothesized that ROTEM-based decision-making will lead to a reduction in pre-procedural blood component usage, particularly fresh frozen plasma (FFP), compared with standard of care, whilst maintaining optimal clinical outcomes. The investigators will perform a prospective, single-center, randomized controlled clinical trial in a tertiary university hospital in Romania, comparing ROTEM-guided prophylactic blood component administration to standard of care in patients with decompensated cirrhosis and coagulopathy undergoing invasive procedures. Inclusion criteria: adults (aged 18 years or older) admitted with cirrhosis and an indication for high risk of bleeding invasive procedure defined as: transjugular liver biopsy, transjugular intrahepatic portosystemic shunt, endoscopic retrograde cholangio-pancreatography with sphincterotomy, endoscopic polypectomy of polyps more than 1 cm, variceal banding and complex dental extraction. The primary safety endpoint will be the incidence of major bleeding. Secondary endpoints will be the proportion of blood products transfusion, hospital length of stay, in-hospital and 28-day mortality, incidence of minor bleeding, transfusion related adverse reactions, and cost analysis.

Read the detailed description

This project will compare two blood transfusion protocols (coagulogram-based and thromboelastometry-based) prior to high risk of bleeding procedures in patients with cirrhosis. The investigators hypothesized that thromboelastometry-guided transfusion protocols are safe and would decrease the need of blood products transfusion compared to an ordinary coagulogram-based protocol in patients with decompensated cirrhosis receiving high risk of bleeding procedures.

03

Conditions studied

  • Liver Cirrhosis With Acute Decompensation

Browse trials for

Keywords

  • ROTEM
  • decompensated liver cirrhosis
  • bleeding risk
  • blood product transfusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with decompensated liver cirrhosis of any etiology
  • planned for a high risk of bleeding invasive procedure
  • coagulopathic based on conventional coagulation tests and considered for pre-procedural blood component prophylaxis
  • able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • acute liver failure
  • current use of anticoagulant treatment
  • patients on antiplatelet aggregation agents
  • patients who have received FFP, transfusion, cryoprecipitate in the week prior to the procedure
  • patients with stage 4 or 5 chronic kidney disease or patients receiving renal replacement therapy
  • sepsis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    Takes into account the SCTs -PT/INR, platelet count and serum fibrinogen levels to guide transfusion prior to high risk of bleeding invasive procedure. If INR ≤1.8, platelet count ≥50,000/mm3 and serum fibrinogen ≥120 mg/dL, no transfusion is indicated. Otherwise, if INR \>1.8, FFP is transfused at 10 mL per kg of body weight; and/or if platelet count \<50,000/mm3, 1 unit per 10 kg of body weight of platelets (up to 10 units) is transfused; and/or if serum fibrinogen \<120 mg/dL, 1 unit per 10 kg of body weight of cryoprecipitate is transfused (up to 10 units).

    Procedure: Blood Products transfusion

  • Experimental
    ROTEM-based

    The thromboelastometry-based transfusion protocol uses EXTEM and FIBTEM. No transfusion is necessary when CT-EXTEM is ≤80 s and A10-EXTEM is ≥40 mm. For patients in whom CT-EXTEM is \>80 s, transfusion of 10 mL per kg of body weight of FFP will be performed. If the patient presents an A10-EXTEM \<40 mm, the investigators will further evaluate the A10-FIBTEM. If A10-FIBTEM is ≥10 mm (indicating adequate fibrinogen function), platelet units (1 unit per 10 kg of body weight; maximum 10 units) will be transfused. Otherwise, if A10-FIBTEM is \<10 mm (indicating fibrinogen deficiency), cryoprecipitate (1 unit per 10 kg of body weight; maximum 10 units) will be transfused.

    Procedure: Blood Products transfusion

Interventions

  • ProcedureBlood Products transfusion

    Blood Products transfusion

06

What researchers measure

Primary outcomes

  1. The proportion of patients transfused with any blood product

    This measure represents the percentage of patients within the study population who received at least one transfusion of any blood component during study period. It is calculated by dividing the number of patients who were administered one or more units of a blood product by the total number of eligible patients in the cohort, and multiplying by 100 to express the result as a percentage. Blood products include platelets, fresh frozen plasma, or cryoprecipitate.

    Time frame: From the enrollment to 30 days after the procedure

  2. The incidence of major bleeding within the first 24 h

    The incidence of major bleeding within the first 24 h after high risk of bleeding invasive procedures. It quantifies early clinically significant hemorrhagic complications and is typically expressed as a percentage or rate. For the purposes of this measure, major bleeding is defined according to standardized clinical criteria. Commonly applied definitions include adapted criteria from the International Society on Thrombosis and Haemostasis (ISTH) or similar consensus frameworks. A bleeding event is classified as major if it meets one or more of the following conditions: fatal bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, pericardial, or intramuscular with compartment syndrome), a decrease in hemoglobin of ≥2 g/dL (≥20 g/L) within 24 hours attributable to bleeding , transfusion of ≥2 units of packed red blood cells due to acute blood loss, bleeding requiring urgent procedural or surgical intervention.

    Time frame: From the enrollment to 30 days after the procedure

Secondary outcomes

  1. The incidence of acute transfusion-related adverse events

    This measure represents the proportion of transfusion episodes that are complicated by an acute transfusion-related adverse event occurring during or within 24 hours after the administration of a blood component. It will be expressed as a percentage and it will be calculated by dividing the number of transfusion episodes complicated by at least one qualifying acute adverse event by the total number of transfusion episodes administered during the study period. An acute transfusion-related adverse event is defined as a new clinical sign or symptom occurring during transfusion or within 24 hours after completion, for which a causal relationship to the transfused blood component is suspected, probable, or definite. The investigators will evaluate transfusion-associated cardiac overload, acute hemolytic transfusion reactions, anaphylactic reactions, febrile non-hemolytic reactions and urticarial reactions.

    Time frame: From enrollment to 30 days after the procedure

  2. The hospital length of stay

    The investigators will evaluate the hospital length of stay in both study arms

    Time frame: From enrollment to 30 days after the procedure

  3. In hospital mortality

    This measure represents the proportion of patients who die from any cause during hospital admission. It captures all-cause mortality occurring between the time of hospital admission and discharge and is typically expressed as a percentage of the total eligible patient population.

    Time frame: From the enrollment to discharge or death

  4. 30-days mortality

    This measure represents the proportion of patients who die from any cause within 30 days of a defined index event. The index event will be high risk of bleeding invasive procedure. The outcome will be expressed as a percentage and will reflect short-term mortality risk beyond the inpatient setting. 30-day mortality is defined as death from any cause occurring within 30 calendar days of the high risk of bleeding invasive procedure regardless of whether the patient is hospitalized, discharged, or transferred at the time of death. Mortality status will be evaluated through telephone follow-up with patients or family members

    Time frame: From date of randomization until the end of the study or the date of death from any cause, whichever came first, assessed up to 30 days.

07

Study locations

1 of 1 sites recruiting
  • Institute of Gastroenterology and Hepatology
    Iași, Iaşi 700111, Romania
    Recruiting
    • Cristina Muzica, Lecturer, MD, PhD · Contactlungu.chirstina@yahoo.com · +40747521793
    • · Contactgilda_iri25@yahoo.com
    • Irina Girleanu, Associated Professor, MD, PhD · Principal investigator
    • Cristina Muzica, Lecturer, MD, Phd · Sub investigator
    • Laura Huiban, Lecturer · Sub investigator
    • Sebastian Zenovia, Teaching Assistant, MD, PhD · Sub investigator
    • Iulian Buzincu, Teaching Assistant, MD, PhD · Sub investigator
    • Raluca Avram, Teaching Assistant, MD · Sub investigator
08

References and documents

Publications

  • Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Jan;73(1):366-413. doi: 10.1002/hep.31646. Epub 2021 Jan 20. No abstract available. PubMed 33219529 ↗
  • Riescher-Tuczkiewicz A, Caldwell SH, Kamath PS, Villa E, Rautou PE; Bleeding in liver diseases investigatorsdagger; Bleeding in liver diseases investigators. Expert opinion on bleeding risk from invasive procedures in cirrhosis. JHEP Rep. 2023 Dec 19;6(3):100986. doi: 10.1016/j.jhepr.2023.100986. eCollection 2024 Mar. PubMed 38384669 ↗
  • Tangcheewinsirikul N, Moonla C, Uaprasert N, Pittayanon R, Rojnuckarin P. Viscoelastometric versus standard coagulation tests to guide periprocedural transfusion in adults with cirrhosis: A meta-analysis of randomized controlled trials. Vox Sang. 2022 Apr;117(4):553-561. doi: 10.1111/vox.13225. Epub 2021 Dec 15. PubMed 34911140 ↗
  • Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology. 2021 Nov;161(5):1630-1656. doi: 10.1053/j.gastro.2021.09.004. Epub 2021 Sep 25. No abstract available. PubMed 34579937 ↗
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022 May;76(5):1151-1184. doi: 10.1016/j.jhep.2021.09.003. Epub 2022 Mar 15. PubMed 35300861 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 27, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Oct 31, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07437755
Lead sponsor
Grigore T. Popa University of Medicine and Pharmacy
Responsible party
Irina Girleanu (Associated Professor, Grigore T. Popa University of Medicine and Pharmacy) — Principal investigator
First posted
Feb 27, 2026
Start date
Jun 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Irina Girleanu, Associated Professor
Contact
gilda_iri25@yahoo.com
+40762278575
Irina Girleanu, Associated Professor
principal investigator · Grigore T. Popa University of Medicine and Pharmacy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion